2023

INDUSTRYAYURVEDIC ANDDATAPHARMACEUTICAL SECTORBOOK



PHARMACEUTICAL INDUSTRY

MINISTRY OF INDUSTRIES

List of Contributors

01.	Mr. A.H.M.U. Aruna Banadara	-	Director General
02.	Miss. Samangika Abeysinghe	-	Acting Director
03.	Mr. G.D.P. Munidasa	-	Acting Director
04.	Miss. W.P. Kalyani	-	Deputy Director
05.	Mr. B.A.K. Heshan	-	Statistician
06.	Mr. P.A.N.C. Pathiraja	-	Development Officer
07.	Mr. W.A.S.R. Jayawardhane	-	Development Officer

Statistics Unit

Planning Division

Ministry of Industries

P.O.Box 570,73/1, Galle road, Colombo 03

Telephone	:	+94 11 2431342
E-mail	:	plan_unit@yahoo.com
Website	:	www.industry.gov.lk

Foreword

The 2023 Industrial Data Book represents our commitment to supporting industrialists as they face current economic challenges and strive for sustainable development through improved decision-making. This data book primarily concentrates on the statistical factors that impact economic growth, particularly focusing on export expansion.

The statistical analyses presented in this data book are based on comprehensive statistical data sourced from various institutions, including the Department of Census and Statistics (DCS), the Department of Customs (DoC), the Export Development Board (EDB) and the Central Bank of Sri Lanka (CBSL).

Within this publication, you will find statistical references related to both exports and imports. This includes tables featuring productivity indicators derived from manufacturing establishments and the number of individuals employed in each sector, as well as statistics on key indicators of industrial activity spanning from 2016 to 2020. The data also covers the value of outputs and output components, intermediate consumption values, employment breakdowns by nature, economic indicators categorized by industry class, and import and export statistics.

I extend my gratitude to Mr. Aruna Bandara, Director General of the Planning Division at the Ministry of Industries, and his dedicated team for their unwavering support throughout this project. I would also like to express my sincere appreciation to Mr. Kavishka Heshan, Statistician at the Ministry of Industries, and his team members, Mr. Nirosh Chathuranga Pathiraja and Mr. Shamith Rashmika Jayawardane, for their remarkable dedication and collaborative efforts with the DCS, which helped make this data book a reality.

I firmly believe that the 2023 Industrial Data Book will play a crucial role in shedding light on current and future productivity and economic growth trends within the industrial sectors. It has the potential to significantly influence policymaking in the industry sectors and will be valuable to a wide range of data consumers, including policymakers, economic planners, academics, researchers and other interested parties in the future.

J.M. Thilaka Jayasundara Secretary Ministry of Industries

Content

	Page No :
Overview	01
Tables of Data and Graphs of Data	02 - 11

List of Tables

Table 1.	Pharmaceutical Products Sector Contribution to the GDP at Current and Constant Market Price (2018 - 2022)	02
Table 2.	Manufacturing Establishments and Number of Persons Engaged of Pharmaceutical Industry (2016-2020)	03
Table 3.	Principal Indicators of Industrial Activity Classified by Persons Engaged Size Class of Pharmaceutical Products (2016) - Establishments with 5 or more persons engaged	03
Table 4.	Principal Indicators of Industrial Activity Classified by Persons Engaged Size Class of Pharmaceutical Products (2017) - Establishments with 5 or more persons engaged	03
Table 5.	Principal Indicators of Industrial Activity Classified by Persons Engaged Size Class of Pharmaceutical Products (2018) - Establishments with 5 or more persons engaged	04
Table 6.	Principal Indicators of Industrial Activity Classified by Persons Engaged Size Class of Pharmaceutical Products (2019) - Establishments with 5 or more persons engaged	04
Table 7.	Principal Indicators of Industrial Activity Classified by Persons Engaged Size Class of Pharmaceutical Products (2020) - Establishments with 5 or more persons engaged	04
Table 8.	Manufacturing of Pharmaceutical Products Per Head Labour Productivity and cost	05
Table 9.	Value of Output & Output Components Classified by Basic Pharmaceutical Products industry - Establishments 25 or more engaged	05
Table 10.	Value of Intermediate Consumptions & Intermediate Consumptions Components Classified by Basic Pharmaceutical Products Industry (Establishment with 25 or more persons engaged)	05
Table 11.	Employment by Nature of Employment & Gender Classified by Industry Division of Basic Pharmaceutical Products (Establishment with 25 or more persons engaged)	06
Table 12.	Economic Indicators of Industrial Activity Classified by Class Industry of Basic Pharmaceutical Products	06
Table 13.	Categories of Employees by Nature of Employment Classified by Industry of Basic Pharmaceutical Products	06
Table 14.	Pharmaceutical Products Export (2020-2022)	07
	Pharmaceutical Products Re-Export (2022)	09
	Pharmaceutical Products Import (2020-2022)	10

-

List of Figures

Figure 1.	The Contribution of the Pharmaceutical Products Industry Sector to the GDP	02
Figure 2. Figure 3.	The Share of the Pharmaceutical Products Industry Sector to the GDP Manufacturing of Pharmaceutical Products Per Head Labour Productivity and cost	02 05
Figure 4.	Major export countries of pharmaceutical products (Glands and other organs for organotherapeutics uses, dried, whether or not powdered) (HS Code 3001) - 2022	08
Figure 5.	Major export countries of pharmaceutical products (Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses) (HS Code 3002) - 2022	08
Figure 6.	Major export countries of pharmaceutical products - Medicaments (excluding goods of heading 30.02, 30.05 or 30.06) (HS Code 3003) - 2022	08
Figure 7.	Major export countries of Medicaments (excluding goods of heading 30.02, 30.05 or 30.06) (HS Code 3004) - 2022	08
Figure 8.	Major export countries of pharmaceutical products - Wadding, gauze, bandages and similar articles (HS Code 3005) - 2022	08
Figure 9.	Major Export Countries of Pharmaceutical goods specified in Note 4 to this chapter (HS Code 3006) - 2022	08
Figure 10.	Major Import Countries of Pharmaceutical Products (Glands and other organs for organ therapeutic uses, dried, whether or not powdered) (HS Code 3001) - 2022	11
Figure 11.	Major Import Countries of Pharmaceutical Product (Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses) (HS Code 3002) - 2022	11
Figure 12.	Major Import Countries of Medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses (HS Code 3003) - 2022	11
Figure 13.	Major Import Countries of Medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of mixed or unmixed products for therapeutic or prophylactic uses (HS Code 3004) - 2022	11
Figure 14.	Major Import Countries of Wadding, gauze, bandages and similar articles (HS Code 3005) - 2022	11

Figure 15. Pharmaceutical goods specified in Note 4 to this chapter. (HS Code 3006) 11 - 2022

Overview

As of 2022, the pharmaceutical industry in Sri Lanka continues to be a vital sector contributing to the nation's healthcare system and economy.

Market Dynamics: The pharmaceutical market in Sri Lanka is growing steadily, driven by factors such as an increasing population, rising income levels, and expanding healthcare infrastructure. The demand for pharmaceutical products, including prescription drugs, over-the-counter medications, and medical devices, continues to rise.

Local Manufacturing: Sri Lanka has a well-established local pharmaceutical manufacturing sector. Several companies produce a wide range of generic drugs to cater to the needs of the local market. These companies play a crucial role in providing affordable healthcare solutions to the population.

Imported Pharmaceuticals: While local manufacturing meets a significant portion of the demand, Sri Lanka also imports pharmaceutical products, particularly high-value patented drugs and specialized medications that are not produced domestically. This import segment contributes to the diversity of pharmaceutical options available in the market.

Regulatory Framework: The pharmaceutical industry in Sri Lanka operates under the oversight of the National Medicines Regulatory Authority (NMRA). The NMRA regulates the registration, quality control, and distribution of pharmaceutical products to ensure safety, efficacy, and adherence to standards.

Investment and Innovation: Local pharmaceutical companies in Sri Lanka are investing in research and development to innovate and improve existing formulations or develop new drugs. Collaboration with international partners and adoption of advanced technologies contribute to enhancing the competitiveness of the industry.

Healthcare Access: Access to essential medicines remains a priority for Sri Lanka's healthcare system. Government initiatives aim to improve access to affordable medicines, especially for underserved populations in rural areas. Efforts are made to ensure the availability of a wide range of pharmaceutical products across the country.

Public Health Challenges: Like many countries, Sri Lanka faces public health challenges such as noncommunicable diseases, infectious diseases, and antimicrobial resistance. The pharmaceutical industry plays a crucial role in addressing these challenges by providing medications, vaccines, and other healthcare solutions.

COVID-19 Response: The COVID-19 pandemic has significantly impacted the pharmaceutical industry in Sri Lanka, leading to increased demand for certain medications, medical supplies, and vaccines. The industry has responded by ramping up production, ensuring the availability of essential drugs, and contributing to the national vaccination drive.

Export Potential: Sri Lanka's pharmaceutical industry has export potential, particularly in the production of generic drugs and traditional herbal medicines. With a focus on quality manufacturing and compliance with international standards, Sri Lankan pharmaceutical companies can explore export opportunities to regional and global markets.

Overall, the pharmaceutical industry in Sri Lanka in 2022 continues to evolve, driven by growth opportunities, regulatory advancements, and efforts to improve healthcare access and quality. Collaboration between the government, industry stakeholders, healthcare providers, and international partners is essential for sustaining growth and addressing emerging healthcare challenges.

Table 1: Pharmaceutical Products Sector Contribution to the GDP at Current and Constant Market Price (2018 - 2022) – (Based on Updated base year 2015)

	Curre	ent	Constant		
Year	Contribution Value (Rs. Mn)	Share of total Current GDP (%)	Contribution Value (Rs. Mn)	Share of total Constant GDP (%)	
2018	8,525	0.06	7,041	0.05	
2019	7,729	0.05	5,818	0.04	
2020	8,400	0.05	6,855	0.05	
2021	9,947	0.06	7,052	0.05	
2022	12,566	0.05	5,066	0.04	

Source: Department of Census and Statistics




Figure 1: The Contribution of the Pharmaceutical Products Industry Sector to the GDP




Figure 2: The Share of the Pharmaceutical Products Industry Sector to the GDP

2

Table 2: Manufacturing Establishments and Number of Persons Engaged of Pharmaceutical Industry (2016-2020)

Year	Establishments 5 engag		Establishments 25 e engag		Total		
	No. ofNo. PersonsEstablishmentsengaged		No. of Establishments			No. Persons engaged	
2016	50	736	34	3,275	84	4,011	
2017	74	842	25	3,146	99	3,988	
2018	63	776	20	2,982	83	3,758	
2019	68	637	18	2,825	86	3,462	
2020	43	456	23	2,453	66	2,909	

Source: Department of Census and Statistics, Annual Survey of Industries

Table 3: Principal Indicators of Industrial Activity Classified by Persons Engaged Size Class of Pharmaceutical Products (2016) - Establishments with 5 or more persons engaged

-												
2016												
Size Class	No. of Establishments	No. of Persons engaged	No. of Employees	Salary & Wages (Rs.)	Output (Rs.)	Intermediate consumptions (Rs.)	Value added (Rs.)	Gross addition to fixed assets (Rs.)				
less than 10	9	73	63	17,262,000	78,437,350	37,919,684	40,517,666	-				
10 to 99	71	2,676	2,546	466,678,565	4,042,684,190	1,928,999,568	2,113,684,621	247,918,246				
100 & above	4	1,262	1,250	675,348,972	6,711,491,223	2,666,798,275	4,044,692,949	433,397,579				
Group total	84	4,011	3,859	1,159,289,537	10,832,612,763	4,633,717,527	6,198,895,236	681,315,825				

Source: Department of Census and Statistics, Annual Survey of Industries

Table 4: Principal Indicators of Industrial Activity Classified by Persons Engaged Size Class of Pharmaceutical Products (2017) - Establishments with 5 or more persons engaged

	2017												
Size Class	No. of Establishments	No. of Persons engaged	No. of Employees	Salary & Wages (Rs.)	Output (Rs.)	Intermediate consumptions (Rs.)	Value added (Rs.)	Gross addition to fixed assets (Rs.)					
less than 10	35	220	153	34,019,409	136,572,045	71,836,961	64,735,085	-					
10 to 99	55	1,553	1,486	298,546,377	2,172,436,882	841,318,508	1,331,118,374	12,754,013					
100 & above	9	2,215	2,203	1,009,067,764	9,588,379,742	4,018,380,477	5,569,999,266	687,960,487					
Group total	99	3,988	3,842	1,341,633,550	11,897,388,669	4,931,535,946	6,965,852,725	700,714,500					

Source: Department of Census and Statistics, Annual Survey of Industries

Table 5: Principal Indicators of Industrial Activity Classified by Persons Engaged Size Class of Pharmaceutical Products (2018) - Establishments with 5 or more persons engaged

	2018												
Size Class	No. of Establishments	No. of Persons engaged	No. of Employees	Salary & Wages (Rs.)	Output (Rs.)	Intermediate consumptions (Rs.)	Value added (Rs.)	Gross addition to fixed assets (Rs.)					
less than 10	23	153	96	26,713,742	109,582,634	57,237,086	52,345,548	-					
10 to 99	49	1,110	1,034	254,279,013	1,044,858,956	455,431,752	589,427,204	12,175,152					
100 & above	11	2,495	2,478	1,232,277,365	11,080,050,553	4,851,949,305	6,228,101,247	4,576,181,244					
Group total	83	3,758	3,608	1,513,270,120	12,234,492,143	5,364,618,143	6,869,873,999	4,588,356,396					

Source: Department of Census and Statistics, Annual Survey of Industries

Table 6: Principal Indicators of Industrial Activity Classified by Persons Engaged Size Class of Pharmaceutical Products (2019) - Establishments with 5 or more persons engaged

	2019												
Size Class	No. of Establishments	No. of Persons engaged	No. of Employees	Salary & Wages (Rs.)	Output (Rs.)	Intermediate consumptions (Rs.)	Value added (Rs.)	Gross addition to fixed assets (Rs.)					
less than 10	44	266	156	36,001,867	120,117,831	47,739,427	72,378,404	14,829					
10 to 99	36	977	926	223,233,197	677,293,933	290,299,540	386,994,393	3,250,253					
100 & above	6	2,219	2,207	1,224,741,560	12,836,724,024	5,718,337,441	7,118,386,583	760,306,953					
Group total	86	3,462	3,289	1,483,976,624	13,634,135,788	6,056,376,408	7,577,759,380	763,572,035					

Source: Department of Census and Statistics, Annual Survey of Industries

Table 7: Principal Indicators of Industrial Activity Classified by Persons Engaged Size Class of Pharmaceutical Products (2020) - Establishments with 5 or more persons engaged

	2020													
Size Class	No. of Establishments	No. of Persons engaged	No. of Employees	Salary & Wages (Rs.)	Output (Rs.)	Intermediate consumptions (Rs.)	Value added (Rs.)	Gross addition to fixed assets (Rs.)						
less than 10	30	213	156	27,994,740	98,418,472	59,745,219	38,673,253	29,950						
10 to 99	31	1,203	1,177	340,293,490	2,381,274,618	592,824,671	1,788,449,947	64,363,489						
100 & above	5	1,493	1,485	853,710,134	13,310,186,562	3,686,402,368	9,623,784,194	477,371,568						
Group total	66	2,909	2,818	1,221,998,364	15,789,879,652	4,338,972,258	11,450,907,394	541,765,007						

Source: Department of Census and Statistics, Annual Survey of Industries

Table 8: Manufacturing of Pharmaceutical ProductsPer Head Labour Productivity and cost

Year	Per head Labour cost	Per head Labour Productivity	Labour Cost to productivity ratio
2016	349,202	1,606,348	4.60
2017	349,202	1,813,080	5.19
2018	419,421	1,904,067	4.54
2019	419,421	2,303,971	5.49
2020	433,640	5,603,222	12.92

Source: Department of Census and Statistics, Annual Surveys of Industries

Figure 3: Manufacturing of Pharmaceutical Products Per Head Labour Productivity and cost




Table 9: Value of Output & Output Components Classified by Basic Pharmaceutical Products industry -Establishments 25 or more engaged

Year	Output (Rs.)	Shipped (Rs.)/ products moved of the establishment (Rs.)	Change in Stocks (Rs.)	Industrial services & other revenue (Rs.)
2016	10,482,138,881	9,774,314,753	417,489,834	290,334,294
2017	11,229,193,326	10,807,833,678	407,919,168	13,440,480
2018	11,275,638,945	13,021,320,171	30,983,744	(1,776,664,970)
2019	13,139,873,754	14,207,112,727	82,820,949	(1,150,059,921)
2020	15,527,447,529	14,113,707,527	14,577,101	1,399,162,901

Source: Department of Census and Statistics, Annual Surveys of Industries

Table 10: Value of Intermediate Consumptions & Intermediate Consumptions Components Classified by Basic Pharmaceutical Products Industry (Establishment with 25 or more persons engaged)

Year	Intermediate consumption (Rs.)	Raw materials consumed (Rs.)	Cost of industrial services done by others & other payments (Rs.)	Electricity & fuel consumed (Rs.)
2016	4,469,649,587	3,581,137,376	729,165,628	159,346,583
2017	4,551,757,304	3,777,136,017	593,270,529	181,350,758
2018	4,957,095,662	4,110,118,895	674,414,579	172,562,188
2019	5,854,392,396	4,778,478,435	925,604,173	150,309,788
2020	4,208,974,160	3,389,606,196	724,796,935	94,571,029

Source: Department of Census and Statistics, Annual Surveys of Industries

Table 11: Employment by Nature of Employment & Gender Classified by Industry Division of Basic Pharmaceutical Products (Establishment with 25 or more persons engaged)

Year	Working Proprietors Un (No.)			Unpaid family workers (No.)		Operatives (No.)		Other employees (No.)		ersons ged
Tear	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
2016	21	4	3	-	674	1,120	1,019	435	1,717	1,559
2017	23	2	3	-	858	947	871	443	1,754	1,392
2018	38	4	5	-	876	594	912	545	1,839	1,143
2019	29	3	-	-	891	685	810	406	1,730	1,095
2020	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Source: Department of Census and Statistics, Annual Surveys of Industries

Table 12: Economic Indicators of Industrial Activity Classified by Class Industry of Basic Pharmaceutical Products

Voor	Output per persons engaged (Rs.)		Outpu interm consun	10 C	Output per assets		Value added per persons engaged (Rs.)		Value added per intermediate consumptions		Value added per assets	
rear	Less than	25 or	Less	25 or	Less	25 or	Less	25 or	Less	25 or	Less	25 or
	25 persons	more persons	than 25 persons	more persons	than 25 persons	more persons	than 25 persons	more persons	than 25 persons	more persons	than 25 persons	more persons
2016	476,187	3,200,653	2.14	2.35	1.19	3.10	253,269	1,835,875	1.14	1.35	0.63	1.78
2017	793,535	3,569,356	1.76	2.47	1.12	2.21	342,518	1,614,755	0.76	1.47	0.49	1.31
2018	1,235,636	3,781,234	2.35	2.28	1.38	1.22	710,478	2,118,894	1.35	1.28	0.80	0.68
2019	776,007	4,651,398	2.45	2.24	0.88	2.58	458,886	2,578,995	1.45	1.24	0.52	1.43
2020	575,100	6,331,300	2.02	3.69	0.83	2.46	290,200	4,615,100	1.02	2.69	0.42	1.79

Source: Department of Census and Statistics, Annual Surveys of Industries

Table 13: Categories of Employees by Nature of Employment Classified by Industry of Basic Pharmaceutical Products

		nents with 2! rsons engage		Establishments with less than 25 persons engaged			
Year	Employees (No.)	Skilled (No.)	Unskilled (No.)	Employees (No.)	Skilled (No.)	Unskilled (No.)	
2016	3,247	1,428	366	612	307	113	
2017	3,118	1,185	620	724	473	131	
2018	2,935	943	527	673	393	130	
2019	2,792	993	583	496	314	89	
2020	2,425	1,001	330	393	238	61	

Source: Department of Census and Statistics, Annual Surveys of Industries

Table 14: Pharmaceutical Products Export (2020-2022)

	2	2020	2(021	2022		
Description	QTY (Kg.)	Value (Rs.)	QTY (Kg.)	Value (Rs.)	QTY (Kg.)	Value (Rs.)	
Glands and other organs for organotherapeutics uses, dried, whether or not powdered; extracts of glands or other organs or of their secretions for organo-therapeutic uses; heparin and its salts; other human or animal substances prepared for therapeutic or prophylactic uses, not elsewhere specified or included.	196	14,400	383	34,500	497	41,800	
Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes; vaccines, toxins, cultures of micro- organisms (excluding yeasts) and similar products.	39,943	253,970,817	46,637	310,263,002	45,475	551,327,870	
Medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses, not put up in measured doses or in forms or packings for retail sale.	48,664	64,035,350	53,042	89,364,290	37,692	139,342,503	
Medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packing for retail sale.	232,467	630,144,421	307,320	876,700,053	244,169	1,149,057,047	
Wadding, gauze, bandages and similar articles (for example, dressings adhesive plasters, poultices), impregnated or coated with pharmaceutical substances or put up in forms or packing for retail sale for medical, surgical, dental or veterinary purposes.	91,197	213,948,060	81,502	207,774,796	98,865	437,365,037	
Pharmaceutical goods specified in Note 4 to this chapter.	629	5,183,983	226	3,323,717	637	2,611,307	
Grand Total	413,096	1,167,297,031	489,112	1,487,460,358	427,337	2,279,745,564	

Source: Sri Lanka Customs





Figure 4: Major export countries of pharmaceutical Figure 5: Major export countries of pharmaceutical products (Glands and other organs for organotherapeutics uses, dried, whether or not powdered) (HS Code 3001) - 2022

products (Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses) (HS Code 3002) - 2022



products - Medicaments (excluding goods of heading 30.02, 30.05 or 30.06) (HS Code 3003) - 2022

Figure 6: Major export countries of pharmaceutical Figure 7: Major export countries of Medicaments (excluding goods of heading 30.02, 30.05 or 30.06) (HS Code 3004) - 2022



products - Wadding, gauze, bandages and similar articles (HS Code 3005) - 2022

Figure 8: Major export countries of pharmaceutical Figure 9: Major Export Countries of Pharmaceutical goods specified in Note 4 to this chapter (HS Code 3006) - 2022

Table 15: Pharmaceutical Products Re-Export (2022)


	2022				
Description	QTY (Kg.)	Value (Rs.)			
Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products.	584	52,159,962			
Medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses, not put up in measured doses or in forms or packings for retail sale.	11	122,383			
Medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packing for retail sale.	54,695	1,280,675,225			
Wadding, gauze, bandages and similar articles (for example, dressings adhesive plasters, poultices), impregnated or coated with pharmaceutical substances or put up in forms or packing for retail sale for medical, surgical, dental or veterinary purposes	757	4,410,142			
Pharmaceutical goods specified in Note 4 to this chapter	8,839	66,076,494			
Grand Total	64,887	1,403,444,206			

Source: Sri Lanka Customs

Table 16: Pharmaceutical Products Import (2020-2022)


	20)20	2	021	2022		
Description	QTY (Kg.)	Value (Rs.)	QTY (Kg.)	Value (Rs.)	QTY (Kg.)	Value (Rs.)	
Glands and other organs for organotherapeutics uses, dried, whether or not powdered; extracts of glands or other organs or of their secretions for organo-therapeutic uses; heparin and its salts; other human or animal substances prepared for therapeutic or prophylactic uses, not elsewhere specified or included.	678	668,002	65	595,383	64	1,284,998	
Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products.	217,986	9,489,402,355	606,673	68,075,574,460	125,981	18,912,316,625	
Medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses, not put up in measured doses or in forms or packings for retail sale.	286,154	570,827,969	605,770	1,358,844,681	1,162,762	3,511,358,870	
Medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packing for retail sale.	22,330,762	77,654,918,041	15,297,685	78,037,400,437	11,925,774	112,161,597,030	
Wadding, gauze, bandages and similar articles (for example, dressings adhesive plasters, poultices), impregnated or coated with pharmaceutical substances or put up in forms or packing for retail sale for medical, surgical, dental or veterinary purposes.	484,999	753,924,566	453,816	850,710,304	263,737	807,387,730	
Pharmaceutical goods specified in Note 4 to this chapter.	274,690	2,502,659,744	248,712	2,823,480,729	170,604	2,976,045,922	
Grand Total	23,594,671	19,313,609,072	17,212,723	151,146,605,994	13,648,922	138,369,991,175	

Source: Sri Lanka Customs




Products (Glands and other organs for organ therapeutic uses, dried, whether or not powdered) (HS Code 3001) - 2022

Figure 10: Major Import Countries of Pharmaceutical Figure 11: Major Import Countries of Pharmaceutical Product (Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses) (HS Code 3002) - 2022



- (excluding goods of heading 30.02, 30.05 or 30.06) consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses (HS Code 3003) - 2022
- Figure 12: Major Import Countries of Medicaments Figure 13: Major Import Countries of Medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of mixed or unmixed products for therapeutic or prophylactic uses (HS Code 3004) - 2022



bandages and similar articles (HS Code 3005) - 2022

Figure 14: Major Import Countries of Wadding, gauze, Figure 15: Pharmaceutical goods specified in Note 4 to this chapter. (HS Code 3006) - 2022